A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study is open to adults with advanced germ cell tumours, endometrial cancer, or ovarian cancer whose previous treatments were not successful. People can join the study if they have no remaining treatment options or if standard therapy is not suitable. The purpose of this study is to test increasing doses of BI 3820768 to find a dose that people with these types of cancer can tolerate and that may make tumours shrink. BI 3820768 is a type of treatment that may help the immune system fight cancer. This is the first time BI 3820768 is being tested in humans. The study has 2 parts based on the way BI 3820768 is given. Depending on when participants join the study, they will receive BI 3820768 through one of two ways to inject the study medicine. All participants receive the study medicine. The medicine is given as an injection once a week for 2 cycles of 3 weeks each, followed by doses every 3 weeks. Participants are in the study for up to 3 years if they are benefiting from the treatment. During this time, they visit the study site regularly, and some visits will require overnight stays. Doctors will regularly check the size of the tumour and whether it has spread. Researchers want to find the highest dose of BI 3820768 that participants can tolerate by looking at the number of participants with certain severe health problems. The doctors also regularly check participants' health, take blood samples, and note any unwanted effects.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjent musi mieć ukończone 18 lat.
- •Pacjent musi wyrazić pisemną zgodę na udział w badaniu.
- •Badanie potwierdza obecność specyficznych cech w próbce guza (dla raka endometrium i jajnika).
- •Pacjent musi mieć potwierdzony nowotwór zarodkowy, raka endometrium lub raka jajnika.
- •Choroba pacjenta jest w zaawansowanym stadium lub nawracająca/opororna na leczenie.
- •Pacjent nie reagował na tradycyjne leczenie, nie toleruje go lub nie ma innych opcji leczenia.
- •Ogólny stan zdrowia pacjenta pozwala na udział w badaniu (dobry stan ogólny).
✗ Disqualifies
- •Pacjent przeszedł dużą operację w ciągu ostatnich 28 dni.
- •Pacjent miał inne nowotwory w ciągu ostatnich 3 lat (z pewnymi wyjątkami, np. leczony rak skóry).
- •Pacjent ma przerzuty do opon mózgowo-rdzeniowych lub ucisk na rdzeń kręgowy.
- •Pacjent wymaga leczenia infekcji w ciągu 7 dni przed podaniem pierwszego leku w badaniu.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 22, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (13)
Valkyrie Clinical Trials
Los Angeles, United States
Indiana University
Indianapolis, United States
The University of Texas MD Anderson Cancer Center
Houston, United States
Cliniques Universitaires Saint-Luc
Brussels, Belgium
UZ Leuven
Leuven, Belgium
INS Paoli-Calmettes
Marseille, France
Institut Gustave Roussy
Villejuif, France
Klinikum der Universität München AÖR
München, Germany
Universitätsklinikum Würzburg AÖR
Würzburg, Germany
National Cancer Center Hospital East
Chiba, Kashiwa, Japan
Japanese Foundation for Cancer Research
Tokyo, Koto-ku, Japan
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Clínica Universidad de Navarra - Madrid
Madrid, Spain
Trial contact
Boehringer Ingelheim
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/8/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.